Servier, an international pharmaceutical group, has entered into a definitive agreement with Kaerus Bioscience to acquire KER-0193, a potential treatment for Fragile X syndrome (FXS), the most common genetic cause of autism spectrum disorder (ASD), in a deal valued at up to $450 million.   KER-0193 was discovered and developed by Kaerus Bioscience, a UK headquartered biotechnology company co-founded by Medicxi in 2016. A Phase 1 clinical study of KER-0193 in healthy volunteers has demonstrate...